Effect of Benfotiamine in Podocyte Damage Induced by Peritoneal Dialysis Fluid

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2015 Mar 26

PMID 25806370

Citations 4

Authors

Sandra Muller-Krebs

Katharina Nissle

Julia Tsobaneli

Martin Zeier

Lars Philipp Kihm

Zoltan Kender

Thomas Fleming

Peter Paul Nawroth

Jochen Reiser

Vedat Schwenger

Affiliations

Soon will be listed here.

Abstract

Background: In peritoneal dialysis (PD), residual renal function (RRF) fundamentally contributes to improved quality of life and patient survival. High glucose and advanced glycation end-products (AGE) contribute locally to peritoneal and systemically to renal damage. Integrity of podocyte structure and function is of special importance to preserve RRF. Benfotiamine could counteract the glucose and AGE-mediated toxicity by blocking hyperglycemia-associated podocyte damage via the pentose-phosphate pathway.

Methods: A human differentiated podocyte cell line was incubated with control solution (control), 2.5% glucose solution (glucose), and 2.5% peritoneal dialysis fluid (PDF) for 48 h either ±50 μM benfotiamine. Podocyte damage and potential benefit of benfotiamine were analyzed using immunofluorescence, western blot analysis, and a functional migration assay. For quantitation, a semiquantitative score was used.

Results: When incubating podocytes with benfotiamine, glucose, and PDF-mediated damage was reduced, resulting in lower expression of AGE and intact podocin and ZO-1 localization. The reorganization of the actin cytoskeleton was restored in the presence of benfotiamine as functional podocyte motility reached control level. Decreased level of inflammation could be shown as well as reduced podocyte apoptosis.

Conclusion: These data suggest that benfotiamine protects podocytes from glucose and PDF-mediated dysfunction and damage, in particular, with regard to cytoskeletal reorganization, motility, inflammation, and podocyte survival.

Citing Articles

Thiamine and benfotiamine: Focus on their therapeutic potential.

Bozic I, Lavrnja I Heliyon. 2023; 9(11):e21839.

PMID: 38034619 PMC: 10682628. DOI: 10.1016/j.heliyon.2023.e21839.

Quercetin attenuates the proliferation, inflammation, and oxidative stress of high glucose-induced human mesangial cells by regulating the miR-485-5p/YAP1 pathway.

Wan H, Wang Y, Pan Q, Chen X, Chen S, Li X Int J Immunopathol Pharmacol. 2022; 36:20587384211066440.

PMID: 35129398 PMC: 8832592. DOI: 10.1177/20587384211066440.

miR-30a-5p targets Becn1 to ameliorate high-glucose-induced glomerular podocyte injury in immortalized rat podocyte cell line.

Yang X, Yang M, Chen Y, Qian Y, Fei X, Gong C Am J Transl Res. 2021; 13(3):1516-1525.

PMID: 33841675 PMC: 8014343.

Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.

Hirakawa Y, Inagi R Int J Mol Sci. 2017; 18(1).

PMID: 28106734 PMC: 5297806. DOI: 10.3390/ijms18010174.

References

Muller-Krebs S, Zhang W, Kihm L, Reiser J, Nawroth P, Schwenger V . Glucose effects on the peritoneum: what can we learn from rodent models?. Exp Clin Endocrinol Diabetes. 2012; 120(4):197-8. DOI: 10.1055/s-0032-1304572. View

Muller-Krebs S, Kihm L, Zeier B, Gross M, Deppisch R, Wieslander A . Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest. 2008; 38(5):296-305. DOI: 10.1111/j.1365-2362.2008.01945.x. View

Kihm L, Wibisono D, Muller-Krebs S, Pfisterer F, Morath C, Gross M . RAGE expression in the human peritoneal membrane. Nephrol Dial Transplant. 2008; 23(10):3302-6. DOI: 10.1093/ndt/gfn272. View

Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, Thornalley P . Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes. 2008; 57(10):2809-17. PMC: 2551693. DOI: 10.2337/db06-1003. View

Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R . Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol. 2005; 17(1):199-207. DOI: 10.1681/ASN.2005020155. View

Muller-Krebs S, Weber L, Tsobaneli J, Kihm L, Reiser J, Zeier M . Cellular effects of everolimus and sirolimus on podocytes. PLoS One. 2013; 8(11):e80340. PMC: 3829970. DOI: 10.1371/journal.pone.0080340. View

Huber T, Kottgen M, Schilling B, Walz G, Benzing T . Interaction with podocin facilitates nephrin signaling. J Biol Chem. 2001; 276(45):41543-6. DOI: 10.1074/jbc.C100452200. View

Boulanger E, Wautier M, Gane P, Mariette C, Devuyst O, Wautier J . The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant. 2004; 19(9):2208-16. DOI: 10.1093/ndt/gfh277. View

Rocco M, Soucie J, Pastan S, McClellan W . Peritoneal dialysis adequacy and risk of death. Kidney Int. 2000; 58(1):446-57. DOI: 10.1046/j.1523-1755.2000.00184.x. View

10.

Rico M, Mukherjee A, Konieczkowski M, Bruggeman L, Miller R, Khan S . WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol. 2005; 289(2):F431-41. DOI: 10.1152/ajprenal.00389.2004. View

11.

Reiser J, Kriz W, Kretzler M, Mundel P . The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol. 2000; 11(1):1-8. DOI: 10.1681/ASN.V1111. View

12.

Muller-Krebs S, Kihm L, Madhusudhan T, Isermann B, Reiser J, Zeier M . Human RAGE antibody protects against AGE-mediated podocyte dysfunction. Nephrol Dial Transplant. 2012; 27(8):3129-36. DOI: 10.1093/ndt/gfs005. View

13.

Kihm L, Muller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross M . Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol. 2011; 22(5):914-26. PMC: 3083313. DOI: 10.1681/ASN.2010070750. View

14.

Haag-Weber M, Kramer R, Haake R, Islam M, Prischl F, Haug U . Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant. 2010; 25(7):2288-96. DOI: 10.1093/ndt/gfq087. View

15.

Termorshuizen F, Korevaar J, Dekker F, van Manen J, Boeschoten E, Krediet R . The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2. Am J Kidney Dis. 2003; 41(6):1293-302. DOI: 10.1016/s0272-6386(03)00362-7. View

16.

Brownlee M . Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813-20. DOI: 10.1038/414813a. View

17.

Saleem M, OHare M, Reiser J, Coward R, Inward C, Farren T . A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002; 13(3):630-638. DOI: 10.1681/ASN.V133630. View

18.

Hammes H, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q . Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003; 9(3):294-9. DOI: 10.1038/nm834. View

19.

Bargman J, Thorpe K, Churchill D . Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001; 12(10):2158-2162. DOI: 10.1681/ASN.V12102158. View

20.

Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R . Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. Perit Dial Int. 2001; 20 Suppl 5:S23-7. View